body > *:not(noscript) { display: none !important; } noscript { display: block !important; } .no-js-warning { display: flex !important; min-height: 100vh; align-items: center; justify-content: center; padding: 20px; background: #f8f9fa; text-align: center; } .no-js-card { max-width: 500px; padding: 30px; border-radius: 12px; background: white; box-shadow: 0 10px 30px rgba(0,0,0,0.08); font-family: Arial, sans-serif; } .no-js-card h1 { margin-bottom: 10px; }

JavaScript Required

JavaScript is required for this website to work correctly and provide a smooth user experience. Please enable JavaScript in your browser, then refresh the page.

Top story

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE) November 26, 2025 -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and …

Read full story

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

PharmaProLearn News

Wed, 22 Jan 2025

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

PharmaProLearn News

Wed, 22 Jan 2025